Audentes Therapeutics Inc. Daily Stock Analysis

Daily Stock Analysis, BOLD, Audentes Therapeutics Inc, priceseries

Audentes Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
59.98
Close
59.97
High
59.99
Low
59.97
Previous Close
59.98
Daily Price Gain
-0.01
YTD High
60.00
YTD High Date
Jan 6, 2020
YTD Low
59.81
YTD Low Date
Jan 3, 2020
YTD Price Change
0.14
YTD Gain
0.23%
52 Week High
60.00
52 Week High Date
Jan 6, 2020
52 Week Low
25.41
52 Week Low Date
Nov 18, 2019
52 Week Price Change
27.36
52 Week Gain
83.90%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jun 21. 2017
17.77
Jul 26. 2017
20.93
24 Trading Days
17.76%
Link
LONG
Nov 15. 2017
25.89
Dec 4. 2017
27.57
12 Trading Days
6.48%
Link
LONG
Dec 14. 2017
28.86
Jan 8. 2018
33.55
15 Trading Days
16.25%
Link
LONG
Apr 9. 2018
32.26
Apr 24. 2018
37.42
11 Trading Days
16.01%
Link
LONG
Feb 15. 2019
24.72
Mar 22. 2019
37.22
24 Trading Days
50.58%
Link
LONG
Jul 17. 2019
36.46
Jul 31. 2019
39.00
10 Trading Days
6.97%
Link
Company Information
Stock Symbol
BOLD
Exchange
NasdaqGM
Company URL
http://www.audentestx.com
Company Phone
415-638-6556
CEO
Matthew R. Patterson
Headquarters
California
Business Address
600 CALIFORNIA ST., 17TH FLOOR, SAN FRANCISCO, CA 94108
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001628738
About

Audentes Therapeutics, Inc. is a biotechnology company, which engages on development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. Its products include AT001 for the treatment of X-Linked Myotubular Myopathy, AT002 for the treatment of Pompe disease, and AT003 for the treatment of Catecholaminergic Polymorphic Ventricular Tachycardia. The company was founded by Matthew R. Patterson and Thomas J. Schuetz on November 13, 2012 and is headquartered in San Francisco, CA.

Description

Audentes Therapeutics, Inc., a biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects in the United States. The company is developing four products, including AT132 for the treatment of X-linked myotubular myopathy; AT342 for the treatment of crigler-najjar syndrome type 1; AT307 for the treatment of the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia; and AT982 for the treatment of pompe disease. Audentes Therapeutics, Inc. has a collaboration with the University of Pennsylvania to develop AT342, an AAV gene therapy for Crigler-Najjar Syndrome, an inherited, metabolic liver disease. The company was founded in 2012 and is based in San Francisco, California.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading